Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2009 Jun 3:10:37.
doi: 10.1186/1745-6215-10-37.

Making trials matter: pragmatic and explanatory trials and the problem of applicability

Shaun Treweek  1 , Merrick Zwarenstein
Affiliations
Review

Making trials matter: pragmatic and explanatory trials and the problem of applicability

Shaun Treweek et al. Trials. .

Abstract

Randomised controlled trials are the best research design for decisions about the effect of different interventions but randomisation does not, of itself, promote the applicability of a trial's results to situations other than the precise one in which the trial was done. While methodologists and trialists have rightly paid great attention to internal validity, much less has been given to applicability. This narrative review is aimed at those planning to conduct trials, and those aiming to use the information in them. It is intended to help the former group make their trials more widely useful and to help the latter group make more informed decisions about the wider use of existing trials. We review the differences between the design of most randomised trials (which have an explanatory attitude) and the design of trials more able to inform decision making (which have a pragmatic attitude) and discuss approaches used to assert applicability of trial results. If we want evidence from trials to be used in clinical practice and policy, trialists should make every effort to make their trial widely applicable, which means that more trials should be pragmatic in attitude.

PubMed Disclaimer

Figures

Figure 1
Figure 1
PRECIS diagrams (based on Thorpe et al [29]).
See this image and copyright information in PMC

References

    1. Altman DG, Bland JM. Statistics notes. Treatment allocation in controlled trials: why randomise? BMJ. 1999;318:1209. - PMC - PubMed
    1. Guyatt GH, Haynes RB, Jaeschke RZ, Cook DJ, Green L, Naylor CD, Wilson MC, Richardson WS. Users' Guides to the Medical Literature: XXV. Evidence-based medicine: principles for applying the Users' Guides to patient care. Evidence-Based Medicine Working Group. JAMA. 2000;284:1290–1296. doi: 10.1001/jama.284.10.1290. - DOI - PubMed
    1. Cochrane AL. Effectiveness and efficiency. Random reflections on health services. London, UK: Nuffield Provincial Hospitals Trust; 1972. - PubMed
    1. Schwartz D, Lellouch J. Explanatory and pragmatic attitudes in therapeutical trials. J Chronic Dis. 1967;20:637–648. doi: 10.1016/0021-9681(67)90041-0. - DOI - PubMed
    1. Coca SG, Krumholz HM, Garg AX, Parikh CR. Underrepresentation of renal disease in randomized controlled trials of cardiovascular disease. JAMA. 2006;296:1377–1384. doi: 10.1001/jama.296.11.1377. - DOI - PubMed